Literature DB >> 33481781

Phenoxyalkylimidazoles with an oxadiazole moiety are subject to efflux in Mycobacterium tuberculosis.

Mai B Thayer1, Tanya Parish1,2.   

Abstract

The phenoxyalkylimidazoles (PAI) are an attractive chemical series with potent anti-tubercular activity targeting Mycobacterium tuberculosis respiration. Our aim was to determine if the PAI compounds are subject to efflux. Two analogs containing an oxadiazole had improved potency in the presence of the efflux inhibitors reserpine and carbonyl cyanide m-chlorophenylhydrazine, whereas the potency of analogs with a diazole was not affected.

Entities:  

Year:  2021        PMID: 33481781      PMCID: PMC7822546          DOI: 10.1371/journal.pone.0239353

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  14 in total

Review 1.  Antituberculosis drugs: reducing efflux=increasing activity.

Authors:  Liliana Rodrigues; Tanya Parish; Meenakshi Balganesh; José A Ainsa
Journal:  Drug Discov Today       Date:  2017-01-13       Impact factor: 7.851

2.  The relevance of persisters in tuberculosis drug discovery.

Authors:  Soma Mandal; Samuel Njikan; Anuradha Kumar; Julie V Early; Tanya Parish
Journal:  Microbiology       Date:  2019-02-18       Impact factor: 2.777

3.  Identification of Phenoxyalkylbenzimidazoles with Antitubercular Activity.

Authors:  N Susantha Chandrasekera; Torey Alling; Mai A Bailey; Megan Files; Julie V Early; Juliane Ollinger; Yulia Ovechkina; Thierry Masquelin; Prashant V Desai; Jeffrey W Cramer; Philip A Hipskind; Joshua O Odingo; Tanya Parish
Journal:  J Med Chem       Date:  2015-09-02       Impact factor: 7.446

4.  Microbe Profile: Mycobacterium tuberculosis: Humanity's deadly microbial foe.

Authors:  Stephen V Gordon; Tanya Parish
Journal:  Microbiology       Date:  2018-02-21       Impact factor: 2.777

5.  Mycobacterial Membrane Proteins QcrB and AtpE: Roles in Energetics, Antibiotic Targets, and Associated Mechanisms of Resistance.

Authors:  Luke Bown; Santosh K Srivastava; Brandon M Piercey; Clarissa K McIsaac; Kapil Tahlan
Journal:  J Membr Biol       Date:  2017-11-02       Impact factor: 1.843

6.  Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system.

Authors:  Anna Milano; Maria Rosalia Pasca; Roberta Provvedi; Anna Paola Lucarelli; Giulia Manina; Ana Luisa de Jesus Lopes Ribeiro; Riccardo Manganelli; Giovanna Riccardi
Journal:  Tuberculosis (Edinb)       Date:  2008-10-11       Impact factor: 3.131

7.  Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.

Authors:  Garrett C Moraski; Lowell D Markley; Jeffrey Cramer; Philip A Hipskind; Helena Boshoff; Mai Bailey; Torey Alling; Juliane Ollinger; Tanya Parish; Marvin J Miller
Journal:  ACS Med Chem Lett       Date:  2013-07-11       Impact factor: 4.345

8.  Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB.

Authors:  N Susantha Chandrasekera; Bryan J Berube; Gauri Shetye; Somsundaram Chettiar; Theresa O'Malley; Alyssa Manning; Lindsay Flint; Divya Awasthi; Thomas R Ioerger; James Sacchettini; Thierry Masquelin; Philip A Hipskind; Joshua Odingo; Tanya Parish
Journal:  ACS Infect Dis       Date:  2017-10-31       Impact factor: 5.084

9.  A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis.

Authors:  Juliane Ollinger; Mai Ann Bailey; Garrett C Moraski; Allen Casey; Stephanie Florio; Torey Alling; Marvin J Miller; Tanya Parish
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

10.  Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis.

Authors:  Thomas R Ioerger; Theresa O'Malley; Reiling Liao; Kristine M Guinn; Mark J Hickey; Nilofar Mohaideen; Kenan C Murphy; Helena I M Boshoff; Valerie Mizrahi; Eric J Rubin; Christopher M Sassetti; Clifton E Barry; David R Sherman; Tanya Parish; James C Sacchettini
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.